BioNTech stock jumps 8.66% after DB-1303 meets primary endpoint in breast cancer trial

American depositary shares of BioNTech SE (NASDAQ: BNTX) soared 8.66% on September 5, closing at USD 112.46, after the German biotech firm and its partner Duality Biologics announced that their lead antibody-drug conjugate (ADC) candidate, DB-1303 (also known as BNT323), had successfully met the primary endpoint in a pivotal Phase 3 trial for HER2-positive metastatic or unresectable breast cancer. The sharp intraday gain of $8.96 per share followed a steady rally throughout the day, with the stock briefly touching a high of USD 114.89 before stabilizing.

The news marks the first late-stage success for BioNTech’s oncology pipeline, which has long been overshadowed by its high-profile mRNA-based COVID-19 vaccine. The pivotal trial—conducted by DualityBio in China—compared trastuzumab pamirtecan (BNT323/DB-1303) with approved ADC trastuzumab emtansine (T-DM1), showing superior progression-free survival in a pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) confirmed the result, triggering immediate institutional interest and a reassessment of BioNTech’s long-term oncology strategy.

How significant is the clinical milestone for BioNTech’s oncology pipeline beyond mRNA vaccines?

The clinical success of DB-1303 represents a turning point for BioNTech’s diversification beyond its infectious disease franchise. Trastuzumab pamirtecan is a third-generation topoisomerase-1 inhibitor-based ADC built on DualityBio’s proprietary DITAC (Duality Immune Toxin Antibody Conjugates) platform. By targeting HER2 receptors on solid tumors, including those with low HER2 expression, the candidate exhibits a broader therapeutic potential than traditional HER2-targeted agents.

BioNTech’s Chief Medical Officer and Co-Founder, Prof. Özlem Türeci, described the candidate as a high-potential asset that validates the company’s global oncology ambitions, especially in combination therapies. With over 350,000 new breast cancer cases annually in China, the Chinese trial was both a strategic and scalable proving ground for BNT323’s safety and efficacy.

What are the key takeaways from the Phase 3 trial and how does it compare to existing treatment options?

The Phase 3 trial (NCT06265428) enrolled 228 patients across 48 sites in China, all of whom had HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane-based chemotherapy. Participants were randomized 1:1 to receive either trastuzumab pamirtecan or the approved comparator T-DM1. The primary endpoint was progression-free survival, evaluated by Blinded Independent Central Review under RECIST 1.1 criteria.

According to the data evaluated, trastuzumab pamirtecan met the predefined criteria for efficacy at interim analysis, suggesting a clinically meaningful advantage over T-DM1. Secondary endpoints include overall survival, objective response rate, and safety—data for which will continue to mature and inform global regulatory strategies.

How does this result fit into BioNTech and DualityBio’s broader ADC development strategy?

This marks the first positive Phase 3 readout under the strategic alliance between BioNTech and DualityBio initiated in April 2023. Their collaboration focuses on building a pipeline of differentiated ADCs targeting solid tumors. BioNTech retains global commercial rights outside Mainland China, Hong Kong, and Macau, while DualityBio holds exclusive commercialization rights within those territories.

The positive result adds momentum to the ongoing DYNASTY-Breast02 global Phase 3 trial (NCT06018337), which investigates the use of BNT323 in patients with HR-positive, HER2-low metastatic breast cancer—an underserved subset previously considered less responsive to HER2-targeted therapies. The trial follows encouraging Phase 1/2 data across HER2-expressing solid tumors and sets the stage for further regulatory filings in the U.S. and EU.

What is the potential commercial and regulatory outlook for BNT323/DB-1303 in global oncology markets?

Following the interim Phase 3 success, DualityBio plans to engage with China’s Center for Drug Evaluation (CDE) for a Biologics License Application (BLA) submission. Given the Fast Track and Breakthrough Therapy designations previously awarded by the U.S. Food and Drug Administration for endometrial cancer, BioNTech is expected to pursue parallel development pathways in the U.S. and EU.

From a market potential standpoint, analysts believe that trastuzumab pamirtecan could eventually emerge as a competitor not only to T-DM1 but also to other HER2-targeted ADCs such as Enhertu (trastuzumab deruxtecan), particularly if it proves effective in HER2-low tumors with a more manageable safety profile. Its dual activity across HER2 expression levels and solid tumor types like endometrial and breast cancer also increases its addressable market.

How are institutional investors responding to the stock movement and oncology news flow?

Institutional sentiment turned bullish as BioNTech’s oncology credentials received rare validation outside its vaccine franchise. The trading volume for BNTX shares spiked mid-day on September 5, reflecting renewed confidence in the biopharmaceutical company’s strategic pivot toward targeted therapeutics.

Market capitalization rose significantly following the announcement, briefly pushing the firm toward the upper bound of its recent trading range. The price-to-earnings ratio now stands at 27.00, with the 52-week high of USD 131.49 becoming a potential resistance level if further data validates the drug’s promise. The 52-week low remains at USD 81.20, reinforcing the significance of recent clinical progress in reversing prior investor caution.

While foreign institutional investor (FII) activity in BNTX remained neutral on the day, options flow and biotech ETF exposure suggest increased exposure is likely in the next rebalancing cycle if subsequent data proves consistent.

What’s next for BioNTech and DualityBio following the DB-1303 milestone, and what should investors watch for?

Analysts expect BioNTech to intensify its ADC portfolio strategy, potentially expanding its DITAC-enabled candidates into other solid tumor indications like ovarian, gastric, or lung cancers. The successful execution of DB-1303 could also boost confidence in BioNTech’s broader immunotherapy pipeline, including mRNA-based cancer vaccines and CAR-T programs.

Regulatory engagement with the FDA and EMA is anticipated in the coming quarters. Meanwhile, DualityBio’s clinical-stage portfolio—featuring at least four assets in global trials—may also attract further strategic partnerships or investment interest as the “super ADC” class gains industry traction.

Investors will be closely tracking safety updates from the ongoing global Phase 3 DYNASTY-Breast02 trial (NCT06018337), which is evaluating trastuzumab pamirtecan in patients with hormone receptor-positive, HER2-low metastatic breast cancer—a population with limited targeted therapy options to date. This trial, which builds on earlier Phase 1/2 data showing encouraging efficacy and tolerability in HER2-expressing tumors, is expected to be a bellwether for the antibody-drug conjugate’s broader applicability beyond HER2-high disease. Additionally, upcoming readouts on overall survival (OS) from the Chinese Phase 3 NCT06265428 study will be critical in confirming the durability and long-term clinical benefit of DB-1303, especially in comparison to established HER2-targeted ADCs like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (Enhertu).

Beyond trial endpoints, institutional analysts are also evaluating whether DB-1303—co-developed by BioNTech SE and Duality Biologics—can position itself as a best-in-class HER2 ADC across global markets. With a potentially more manageable safety profile and evidence of activity in both HER2-positive and HER2-low patient populations, BNT323 could redefine the competitive landscape in HER2-driven breast cancer if it continues to deliver on efficacy, progression-free survival, and overall survival metrics. The global oncology community, including KOLs and prescribing oncologists, will be watching closely to determine whether DB-1303 can not only complement but possibly displace current market leaders in the next wave of antibody-drug conjugate innovation for solid tumors.